BriaCell initiates patient enrollment in first-in-human study of Bria-OTS

BriaCell Therapeutics announces initiation of a first-in-human, Phase 1/2 study evaluating safety and efficacy of Bria-OTS, BriaCell’s personalized off-the-shelf next generation immunotherapy, as monotherapy and in combination with PD-1 inhibitor tislelizumab, in advanced metastatic breast cancer. “Advancing Bria-OTS as our second novel immunotherapy candidate into the clinic is a significant milestone for BriaCell. We believe personalization through our Bria-OTS immunotherapy platform will produce more potent and long-lasting responses than previously observed, with potential synergistic effects with the immune check point inhibitor,” stated Dr. William V. Williams, BriaCell’s President & CEO. “We are grateful to our scientific and clinical teams for the successful completion of the Institutional Review Board, Clinical Trial Site Agreement, and obtaining FDA authorization for the Investigational New Drug filings, as well as to our investors and collaborators for their support in bringing Bria-OTS(TM) one step closer to cancer patients.”